Cetuximab is a monoclonal drug that has survival advantage in the treatment of patients with locoregionally advanced and platinum-refractory metastatic or recurrent head and neck squamous cell carcinoma (SCC). We report a case of 52 year-old man with peristomal recurrence of laryngeal SCC patient who was treated successfully with cetuximab,  cisplatin and 5FU after organ preservation treatment and surgery. The patient presented with dysphonia and laryngeal lesions, underwent direct laryngoscopy (DL) with biopsies  and the diagnosis was poorly differentiated SCC. Subsequently, he was treated with chemoradiation therapy. However, he developed hoarseness and dyspnea after chemoradiation. DL was performed due to transglottic lesion with suspicious left level 2A lymph node metastasis. Then, we performed total laryngectomy with neck dissection. Unfortunately, pharyngocutaneous fistula and peristomal recurrence developed after the surgery. The patient received palliative chemotherapy with cetuximab, cisplatin, and 5FU and acheived complete remission. Pharyngocutaneous fistula was closed with deltopectoral fasciocutaneous flap. No signs of recurrence were noted at 18 months followup. Concurrent therapy with cetuximab may be beneficial in patients with recurrent laryngeal cancer.